Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

18 study records (showing up to 30 per record type)

• Registered trial NCT03613740 Phase 2 Not completed: Active Not Recruiting
  Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
  Condition or outcome area: Metabolic Syndrome
  2019-09-30 · Subject: Fucoxanthin; fucoxanthin · open the ingredient record · ClinicalTrials.gov
• Publication PMID 36160416 Research model: Animal & Cell Experiment
  Fucoxanthin prevents breast cancer metastasis by interrupting circulating tumor cells adhesion and transendothelial migration
  Condition or outcome area: tumor; Circulating tumor; cancer; cancer-related death; breast cancer
  Front Pharmacol · 2022 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3389/fphar.2022.960375
• Publication PMID 35565869 Research model: Animal & Cell Experiment
  Fucoxanthin Attenuates the Reprogramming of Energy Metabolism during the Activation of Hepatic Stellate Cells
  Condition or outcome area: liver fibrosis
  Nutrients · 2022 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/nu14091902
• Publication PMID 35447917 Research model: Animal & Cell Experiment
  Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells
  Condition or outcome area: neuronal cell loss; Parkinson's disease; necrosis; neurodegeneration
  Mar Drugs · 2022 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/md20040245
• Publication PMID 35126819 Research model: Animal & Cell Experiment
  Fucoxanthin Attenuates Oxidative Damage by Activating the Sirt1/Nrf2/HO-1 Signaling Pathway to Protect the Kidney from Ischemia-Reperfusion Injury
  Condition or outcome area: renal dysfunction; ischemic stroke; renal ischemia/reperfusion (I/R) injury; acute lung injury; renal I/R injury
  Oxid Med Cell Longev · 2022 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1155/2022/7444430
• Publication PMID 34948416 Research model: Animal Experiment
  Fucoxanthin Prevents Pancreatic Tumorigenesis in C57BL/6J Mice That Received Allogenic and Orthotopic Transplants of Cancer Cells
  Condition or outcome area: adenocarcinoma; tumor; pancreatic cancer; cancer; pancreatic tumors
  Int J Mol Sci · 2021 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/ijms222413620
• Publication PMID 34571188 Research model: Animal Experiment
  Suppression of C-C chemokine receptor 1 is a key regulation for colon cancer chemoprevention in AOM/DSS mice by fucoxanthin
  Condition or outcome area: colorectal adenocarcinoma; cancer
  J Nutr Biochem · 2022 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1016/j.jnutbio.2021.108871
• Publication PMID 34207952 Research model: Cell Experiment
  A Comparative In Vitro Evaluation of the Anti-Inflammatory Effects of a Tisochrysis lutea Extract and Fucoxanthin
  Condition or outcome area: inflammation
  Mar Drugs · 2021 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/md19060334
• Publication PMID 34073219 Research model: Animal & Cell Experiment
  Protective Effects of Fucoxanthin on Hydrogen Peroxide-Induced Calcification of Heart Valve Interstitial Cells
  Condition or outcome area: Cardiovascular diseases; aortic valve sclerosis; heart valve damage; atherosclerosis; heart valve diseases; calcification
  Mar Drugs · 2021 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/md19060307
• Publication PMID 34070405 Research model: Animal & Cell Experiment
  Fucoxanthin Ameliorates Oxidative Stress and Airway Inflammation in Tracheal Epithelial Cells and Asthmatic Mice
  Condition or outcome area: airway hyperresponsiveness; airway inflammation; asthma; goblet cell hyperplasia
  Cells · 2021 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/cells10061311
• Publication PMID 33777321 Research model: Animal & Cell Experiment
  Fucoxanthin Prevents 6-OHDA-Induced Neurotoxicity by Targeting Keap1
  Condition or outcome area: necrosis; neuronal cell loss; Parkinson's disease
  Oxid Med Cell Longev · 2021 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1155/2021/6688708
• Publication PMID 33598775 Research model: Cell Experiment
  Fucoxanthin inhibits lipopolysaccharide-induced inflammation and oxidative stress by activating nuclear factor E2-related factor 2 via the phosphatidylinositol 3-kinase/AKT pathway in macrophages
  Condition or outcome area: tumor
  Eur J Nutr · 2021 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1007/s00394-021-02509-z
• Publication PMID 32876840 Research model: Animal Experiment
  Fucoxanthin Mitigates Subarachnoid Hemorrhage-Induced Oxidative Damage via Sirtuin 1-Dependent Pathway
  Condition or outcome area: acute brain injuries; brain edema; traumatic brain injury; subarachnoid hemorrhage; ischemic stroke
  Mol Neurobiol · 2020 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1007/s12035-020-02095-x
• Publication PMID 32235696 Research model: Animal Experiment
  Fucoxanthin Ameliorates Atopic Dermatitis Symptoms by Regulating Keratinocytes and Regulatory Innate Lymphoid Cells
  Condition or outcome area: atopic dermatitis
  Int J Mol Sci · 2020 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/ijms21062180
• Publication PMID 32232236 Research model: Cell Experiment
  Fucoxanthin alleviates palmitate-induced inflammation in RAW 264.7 cells through improving lipid metabolism and attenuating mitochondrial dysfunction
  Condition or outcome area: mitochondrial dysfunction
  Food Funct · 2020 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1039/d0fo00442a
• Publication PMID 32033492 Research model: Cell Experiment
  Skin Irritation Testing beyond Tissue Viability: Fucoxanthin Effects on Inflammation, Homeostasis, and Metabolism
  Pharmaceutics · 2020 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.3390/pharmaceutics12020136
• Publication PMID 21078541 Research model: Animal & Cell Experiment
  Fucoxanthin and its deacetylated product, fucoxanthinol, induce apoptosis of primary effusion lymphomas
  Condition or outcome area: Primary effusion lymphoma
  Cancer Lett · 2011 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1016/j.canlet.2010.10.016
• Publication PMID 24760606 Research model: Cell Experiment
  Inhibitory effects of fucoxanthinol on the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 are correlated with modulation of the NF-kappaB pathway
  Condition or outcome area: cancers || breast cancer
  Cell Biol Toxicol · 2014 · Subject: Fucoxanthin; 3351-86-8; all-trans-Fucoxanthin; 06O0TC0VSM; CHEBI:5186; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one; (1S,3R)-3-hydroxy-4-((3E,5E,7E,9E,11E,13E,15E)-18-((1S,4S,6R)-4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl)-3,7,12,16-tetramethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate; (3S,3'S,5R,5'R,6S,6'R)-3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahyd · open the ingredient record · DOI 10.1007/s10565-014-9277-2